Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus
- 1 July 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (7) , 3162-3165
- https://doi.org/10.1128/aac.00093-09
Abstract
Vancomycin and daptomycin MIC results for 1,800 randomly selected oxacillin (methicillin [meticillin])resistant Staphylococcus aureus (MRSA) bloodstream isolates from nine U. S. hospitals (collected from 2002 to 2006) were determined by a reference broth microdilution (BMD) method using frozen-form panels with precise incremental dilutions and by the Etest technique. The Etest provided vancomycin and daptomycin MIC results that were consistently higher (0.5 to 1.5 log(2) dilution steps) than those provided by the reference BMD method. The dominant MRSA population (91.2% of MRSA isolates) would be categorized as vancomycin nonsusceptible by the MIC results from the Etest method if the susceptibility breakpoint was adjusted downward to <= 1 mu g/ml, as suggested by clinical outcome studies.This publication has 12 references indexed in Scilit:
- Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infectionsInternational Journal of Antimicrobial Agents, 2008
- Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006Clinical Infectious Diseases, 2008
- Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus BacteremiaClinical Infectious Diseases, 2008
- Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infectionsAnnals of Clinical Microbiology and Antimicrobials, 2007
- Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05Journal of Antimicrobial Chemotherapy, 2007
- High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus InfectionsArchives of internal medicine (1960), 2006
- Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant StrainsClinical Infectious Diseases, 2006
- Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus BacteremiaJournal of Clinical Microbiology, 2004
- Treatment Outcomes for Serious Infections Caused by Methicillin‐ResistantStaphylococcus aureuswith Reduced Vancomycin SusceptibilityClinical Infectious Diseases, 2004
- Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract InfectionsClinical Pharmacokinetics, 2004